** Shares of medical device maker Zimmer Biomet ZBH.N up 1.3% at 108.25 premarket
** Brokerage J.P.Morgan upgrades stock to "overweight" from "neutral"; raises PT to $128 from $125
** Says an improved product portfolio on top of healthy volumes and less negative pricing should support growth, despite lack of conviction in execution following supply headwinds that impacted the last few quarters
** Believes in the growth despite concern around current Street expectations for 2025 along with sustainability of growth for co and orthopedics end market
** Says reacceleration in softness in comps for the first half and new product contribution could drive upside; hopeful to see upside in annual gross margin guidance
** 11 of 31 brokerages rate the stock "buy" or higher, 18 "hold" and two "sell"; with a median PT of $122.50
** Up to Monday's close, stock has fallen ~12% YTD
(Reporting by Neil J Kanatt in Bengaluru)
((Neil.JKanatt@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。